Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem-Vaborbactam TQT Study
NCT03564158Phase 1Completed
- Sponsor
- Rempex Pharmaceuticals
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vaborbactam in complicated urinary tract infection (cUTI) (4 arms), sponsored by Rempex Pharmaceuticals. Primary endpoint: Placebo-corrected change-from-baseline QTcF interval at 24 hours. Started May 2018; status: completed.
02
Drugs
vaborbactam
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT03564158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564158.